FDA staff question benefit of AstraZeneca ovarian cancer drug

June 23, 2014 3:11 PM

11 0

FDA staff question benefit of AstraZeneca ovarian cancer drug

(Reuters) - AstraZeneca Plc's experimental ovarian cancer drug, olaparib, showed an 83 percent reduction in the risk of disease progression, but a U.S. Food and Drug Administration staff review has questioned whether the result could be reproduced.

The company's shares fell 1.8 percent to 43.89 pounds on the London Stock Exchange.

Read more

To category page

Loading...